Atara Biotherapeutics
ATRA
82 hedge funds and large institutions have $57.9M invested in Atara Biotherapeutics in 2024 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 25 increasing their positions, 29 reducing their positions, and 25 closing their positions.
142% more capital inflows, than outflows
Capital inflows: $23.8M | Capital outflows: $9.82M
18.19% more ownership
Funds ownership: 63.53% → 81.71% (+18%)
9% less funds holding
Funds holding: 90 → 82 (-8)
14% less repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 29
15% less call options, than puts
Call options by funds: $33K | Put options by funds: $39K
32% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$4.54M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$4.44M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$3.48M |
| 4 |
BC
Boxer Capital
San Diego,
California
|
+$2.95M |
| 5 |
Vestal Point Capital
New York
|
+$1.99M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$2.55M |
| 2 |
Millennium Management
New York
|
-$1.82M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.19M |
| 4 |
JP Morgan Chase
New York
|
-$594K |
| 5 |
D.E. Shaw & Co
New York
|
-$530K |
ATRA Hedge Fund Activity: Q1 2024 in Review
82 of the 6,963 institutional investors tracked by Wall St. Rank reported a position in Atara Biotherapeutics (ATRA) for Q1 2024, worth a combined $57.9M — up 74% from $33.2M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of ATRA and 17 opened new positions — a net loss of 8 holders — while 29 trimmed existing stakes and 25 added.
The largest buyer was Bank of America, adding an estimated $4.54M. The largest seller was UBS Group, cutting an estimated $2.55M.
- 82 institutional investors held Atara Biotherapeutics (ATRA) as of Q1 2024, down from 90 in Q4 2023.
- Funds reported $57.9M of Atara Biotherapeutics stock for Q1 2024, up 74% quarter-over-quarter.
- 17 funds opened new Atara Biotherapeutics positions in Q1 2024 and 25 closed out, a net change of -8 holders.
- The largest Atara Biotherapeutics buyer in Q1 2024 was Bank of America, an estimated $4.54M added.
- The largest Atara Biotherapeutics seller in Q1 2024 was UBS Group, an estimated $2.55M sold.
Based on aggregated 13F filings for Q1 2024.